Asset
MIFEPRISTONE
Corcept Therapeutics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00698022 | phase1 | completed | 2008-11-01 | 2009-02-01 | Corcept Therapeutics | A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers |
| NCT00752843 | phase1 | completed | 2008-09-01 | 2008-11-01 | Corcept Therapeutics | A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers |
| NCT00637494 | phase3 | terminated | 2008-03-01 | 2014-06-01 | Corcept Therapeutics | A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features |
| NCT00569582 | phase3 | completed | 2007-12-01 | 2011-01-01 | Corcept Therapeutics | A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome |
| NCT00455442 | phase2 | completed | 2007-03-01 | — | Corcept Therapeutics | A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 202107 | NDA | CORCEPT THERAPEUTICS INC |
Marketed products (1)
- KORLYM